Kei Muro

34PUBLICATIONS
171CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsChemotherapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|May 05, 2026
Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.

|Apr 13, 2026
Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study.

Kazunori Honda, Kazuhiro Shimomura, Hiroya Taniguchi

|Apr 03, 2026
Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer.

Daniel Walden, Felipe Batalini, Cody Eslinger

|Mar 12, 2026
Regorafenib in refractory gastric cancer: modest median, meaningful milestone.

Yukiya Narita, Kei Muro

|Mar 06, 2026
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study.

Yukiya Narita, Hisato Kawakami, Koki Nakanishi

|Feb 02, 2026
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima

Pageof 6

Frequent Collaborators

9 joint publications

Yukiya Narita

4 joint publications

Shigenori Kadowaki

4 joint publications

Hisato Kawakami

3 joint publications

Toshiki Masuishi